Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Active Biotech Interim Report: Phase II Projects Proceeds According to Plan.


Business Editors/Health & Medical Writers

LUND, Sweden--(BUSINESS WIRE)--Aug. 15, 2002

Swedish biotech company Active Biotech is a world leader in terms of the development of new drugs in tablet form for the treatment of MS.

Our ongoing SAIK-MS Phase II trial in patients proceeds according to plan.

The company also develops new pharmaceuticals for use in the treatment of cancer (renal, lung and pancreas). In this area our TTS (1) See text-to-speech.

(2) (Transaction Tracking System) Software that monitors a transaction until completion. In the event of a hardware or software failure, it ensures that the database is brought back to its former state before the attempt to
 Phase II cancer studies advance according to plan where renal and pancreatic cancer patients now receives treatment. Our TASQ TASQ Transparent Auto-Switch Quality (Quitum Technologies)
TASQ Tactical Airlift Squadron
 prostate cancer project is in preparation for clinical trials in 2003.

In addition, the company has selected a number of candidate drugs that are currently being prepared for clinical development. Our research organization has generated one candidate drug per year over the last three-year period.

Due to the today released Interim Report for April-June 2002 loss after net financial items improved from SEK SEK

In currencies, this is the abbreviation for the Swedish Krona.

Notes:
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion.
 89.0 m to SEK 68.1 m, the improvement due to focus on core operations. The full Interim Report can be downloaded from: http://reports.huginonline.com/869987/106839.pdf

Active Biotech is listed on the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries.  (ACTI ACTI Advanced Cleanup Technologies, Inc (Rancho Dominguez, CA)
ACTI Advanced Computational Technology Initiative
ACTI Advisory Committee on Technology Innovation
ACTI Aircrew Coordination Training Instructor
 B.SE) and our web address is www.activebiotech.com.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:Active Biotech Interim Report: Phase II Projects Proceeds According to Plan.
Publication:Business Wire
Geographic Code:4EUSW
Date:Aug 15, 2002
Words:204
Previous Article:OuterBounds Technologies, Inc. Signs Application Hosting Contract with Electronic Registry Systems, Inc.
Next Article:Netkey Wins Self-Service `Software Design Excellence' Award For The Second Straight Year From Kiosk Magazine.



Related Articles
SYNSORB Biotech Inc. Reports Third Quarter Results.
SYNSORB Biotech Inc. Reports Third Quarter Results.
ACTIVE BIOTECH: First Data On Efficacy In ETEC-Vaccine by the End of the Quarter; New Investment in Pharmaceuticals Against Cancer.
IMMUNE NETWORK HALTS PHASE I INTERACTION TRIAL.
Active Biotech: Interim Report January - March 2001.
FDA CLEARS THROMBOLYTIC DRUG FOR PHASE II CLINICAL TRIAL.
Active Biotech's drug for the treatment of Multiple Sclerosis.
Active Biotech AB, Announces 2002 Results And A Rights Issue.
GPC BIOTECH GETS GERMANY PERMITS FOR MONOCLONAL ANTIBODY.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles